New hope for hard-to-treat breast cancer: phase 3 trial launches
NCT ID NCT06957886
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called BL-M07D1 against standard chemotherapy in 566 adults with HER2-low breast cancer that has come back or spread. The goal is to see if BL-M07D1 can slow the cancer's growth better than current treatments. Participants must be women aged 18 to 75 with confirmed HER2-low status.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-LOW BREAST CANCER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, Hunan, China
Contact
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, China
Contact